Special considerations before / during / after DAA therapy | Kosh Agarwal, MD

International Workshop on HIV & Hepatitis Co-infection 2017

HBV cure: what is coming in 5 – 10 years? | Patrick Kennedy, MD

International Workshop on HIV & Hepatitis Co-infection 2017

EASL highlights 2017 | Jürgen Rockstroh, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Management of end-stage liver disease in HIV patients | Ana Morbey, MD

International Workshop on HIV & Hepatitis Co-infection 2017

News on hepatitis delta and HIV infections | Vincent Soriano, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Hepatitis E in HIV | Kenneth Sherman, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Management of HCV in intravenous drug users: special considerations | Rui Sarmento e Castro, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

HIV cure and eradication | Ricardo Diaz, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

Present and future of ART in Latin America | Carlos Beltrán, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

Do we really need new drugs? | Mark Nelson, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

The aging HIV infected patient - neurological issues - poly pharmacy | Ernesto Martinez Buitrago, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

HIV in Women - PTMCT - pregnancy | Isabel Cassetti, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

Strategies for hepatitis C elimination | Francesca Ceccherini– Silberstein, PhD

Andean Pacific Workshop on HIV & Hepatitis 2017

Implementation of DAAs in clinical management | Mark Nelson, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

Local situation in LA (epidemiology / treatment options) | Jorge Contreras, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

Early diagnosis & testing | Susana Cabrera, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

Clinical Implications of low level viremia/ failure and resistance | Francesca Ceccherini– Silberstein, PhD

Andean Pacific Workshop on HIV & Hepatitis 2017

Difficult to reach populations in Latin America | Ana Paulina Celi de la Torre, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

WHO Target 90-90-90 : Achievable for Latin America | Alejandro Afani, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

HIV in Latin America: 35 years later | Marcelo Wolff, MD, FACP, FIDSA

Andean Pacific Workshop on HIV & Hepatitis 2017

Prospects for cure | Annemarie Wensing, MD, PhD

European Meeting on HIV & Hepatitis 2018

What is the place of the monoclonal antibodies in the clinic | Julià Blanco, PhD

European Meeting on HIV & Hepatitis 2018

Reduced drug regimens | Andrea De Luca, MD

European Meeting on HIV & Hepatitis 2018

What’s in the pipeline? Presentations by scientists from the industry | Jean-Marc Steens, MD

European Meeting on HIV & Hepatitis 2018